$AKTX

Akari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.

Two U.S. biotech firms, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats. Akston is sponsoring a Cornell study of about 70 cats, while OKAVA is trialing a long-acting implant for up to six months. The drugs are unapproved and results are expected later this year.

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001541157 0001541157 2026-06-30 2026-06-30 0001541157 AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember 2026-06-30 2026-06-30 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbr

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001541157 0001541157 2026-06-23 2026-06-23 0001541157 AKTX:AmericanDepositorySharesEachRepresenting80000OrdinarySharesMember 2026-06-23 2026-06-23 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbr

Akari Therapeutics (NASDAQ:AKTX) saw short interest rise to 64,685 shares as of May 15, up from 16,135 on April 30, with about 8.2% of shares sold short and a short-interest ratio of 1.8 days. Armistice Capital bought 2,723,966 shares in Q4, valuing the stake at ~$787,000 (5.95%). Analysts’ consensus is “Hold” with a $89 target. The stock traded at $16.43; EPS missed on May 20.

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Akari Therapeutics (NASDAQ: AKTX) announced that its President and CEO, Abizer Gaslightwala, will participate in an investor webcast on May 20, 2026, to discuss the company's differentiated antibody drug conjugate (ADC) pipeline. The presentation will focus on its proprietary PH1 RNA splicing modulator payload platform and the lead TROP2-targeting ADC program, AKTX-101. The event is virtual, with registration available online.

This page provides the debt to equity ratio for Akari Therapeutics Plc Sponsored ADR, traded under the symbol CLA1 on the Munich Stock Exchange. It is part of a financial overview for the company, accessible through TradingView. The content primarily displays the financial metric without further descriptive analysis or historical data on this specific page.

Akari Therapeutics reported a net loss of $(17.3) million and operating losses of $(17.3) million, a 20% reduction from the prior year due to lower merger-related and RIF costs. The company significantly cut R&D expenses by 60% to $2.815 million, focusing on its prioritized ADC program, AKTX-101, with a Phase 1 trial targeted for Q1 2027. Akari has shifted its strategic focus to a PH1-based ADC pipeline following a merger and secured multiple financings to support its development.

Akari Therapeutics has initiated GMP manufacturing for its lead antibody-drug conjugate (ADC) program, AKTX-101, partnering with WuXi XDC. This step is crucial for supporting a planned Phase 1 first-in-human clinical trial, expected to begin in late 2026 or early 2027. AKTX-101 uses Akari's proprietary PH1 payload, designed to modulate RNA splicing in cancer cells, offering a differentiated approach with potential cytotoxic and immuno-oncology benefits.